Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Letter
Nature Chemical Biology 1, 333–337 (1 November 2005) | doi:10.1038/nchembio742
Host sphingolipid biosynthesis as a target for hepatitis C virus therapy
&
Abstract
An estimated 170 million individuals worldwide are infected with hepatitis C virus (HCV), a serious cause of chronic liver disease. Current interferon-based therapy for treating HCV infection has an unsatisfactory cure rate, and the development of more efficient drugs is needed.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
